Introduction

32
Artemisinin combination therapy (ACT) is the cornerstone of malaria control programs.
33
However, reports of parasites in Cambodia with decreased in vivo sensitivity to artemisinin 34 (4, 6) have raised serious concerns for the emergence of artemisinin (ART) resistance in the 35 field. To give insight into the mechanisms of ART resistance and to monitor its spread (5) it 36 is critical to characterise the resistant phenotype. To date it has not been well described and 37 no molecular marker has been identified.
38
The clinical data from western Cambodia indicated that parasite clearance times after 39 artesunate mono-therapy were significantly longer than in northwestern Thailand (4).
40
However, few other phenotypic changes were identified. The Thai and Cambodian isolates 41 showed no significant differences in their susceptibility (IC 50 values) to either 42 dihydroartemisinin (DHA) or artesunate when measured using classic in vitro drug 43 susceptibility tests (4).
44
Reduced susceptibility of ring-stage parasites to ART has been proposed as an explanation 45 for the prolonged clearance times observed in Cambodia (4, 7). This hypothesis would 46 explain the results of conventional in vitro susceptibility tests that assess the drug effect on 47 the maturation of parasites from ring to schizont stage (4) and may be supported by an in 48 vitro study showing only ring-stage artemisinin-adapted parasites persisted during 48 hours 49 of drug-pressure (10). In contrast it has been reported that IC 50 values for three laboratory 50 parasite lines, adapted to tolerate 80 ng/ml of artelinic acid (AL), increased 2 to 5 fold (1).
51
These changes were accompanied by increases in copy number, mRNA expression, and 52 protein expression of the pfmdr1 gene. Using one of these adapted parasite lines, increases in 53 IC 50 of up to 12 fold after renewed drug-selection were reported (2). were 10 ng/ml for W2 and 40 ng/ml for D6 and TM91C235. In the resistant lines the growth 110 inhibition thresholds were 2 fold higher for TM91C235AL80 (80 ng/ml), 4 fold for D6AL80 111 (160 ng/ml) and 16 fold higher for W2AL80 (160 ng/ml). These thresholds were consistent 112 when a biological replicate was conducted.
113
Examination of blood smears taken after 30 hours of drug exposure showed a dramatic 114 difference in parasite maturation under drug pressure ( Figure 1A and 1B). In the resistant line 115 W2AL80 more than 80% of the initial ring-stage parasites matured through to trophozoite or 116 schizont stage when exposed to 40 ng/ml or less of AL ( Figure 1A ), and 640 ng/ml of AL 117 was required to almost completely stop parasite maturation. In contrast, less than 20% of AL 118 sensitive ring stage parasites progressed to mature stages when exposed to only 10 ng/ml of 119 AL; development was completely halted at AL concentrations above 10 ng/mL ( Figure 1A ).
120
The same trend was observed in the D6 and TM91C235 parent and resistant lines (data not 121 shown). The quantity of HRP2 in W2AL80 after the 72 hr drug incubation was 2.9-5.8 fold 122 higher than its sensitive parent at drug concentrations ≤ 40 ng/mL (data not shown). In 
Discussion
157
Parasites with decreased in vivo sensitivity to artemisinin have been reported but in vitro 158 these isolates did not appear significantly more resistant than those obtained elsewhere (4).
159
The aim of this study was to define the resistant phenotype by characterizing the growth and proportion increase, reaching ~45% at 320 ng/ml. This is in sharp contrast to W2 where 48% 186 were dormant at 10 ng/ml of AL. These results indicate that dormancy still occurs in the 187 resistant parasite line but that higher drug concentrations are required to induce it. The 188 majority of resistant parasites do not develop dormancy at concentrations they can tolerate.
189
This also suggests that dormancy may be an innate mechanism that parasites use to survive 190 drug concentrations which would otherwise cause severe damage, one that is only triggered 191 when parasite development is significantly inhibited.
192
To monitor recovery from dormancy we exposed W2 and W2AL80 to concentrations well isolates are needed to evaluate this hypothesis. Understanding the phenotype changes which 223 occurred in these resistant parasites will contribute to a better understanding of the resistance 224 mechanisms involved so we can develop tools to monitor for, and contain, ART resistance. 
